Valuation: Avacta Group Plc

Market Cap 337M 446M 396M 370M 635M 42.93B 644M 4.48B 1.73B 21.86B 1.67B 1.64B 70.22B P/E 2026 *
-11.2x
P/E 2027 * -13x
Enterprise Value 335M 443M 393M 368M 631M 42.62B 639M 4.45B 1.72B 21.7B 1.66B 1.63B 69.71B EV / Sales 2026 *
122x
EV / Sales 2027 * 43.7x
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Avacta Group Plc

1 week-1.10%
1 month+7.46%
3 months-0.69%
6 months+13.39%
Current year+24.14%
1 week 71
Extreme 71
75
1 month 65
Extreme 65
88
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Director/Board Member 59 28/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/24 Sell

Chief Financial Officer

500,000 0.1393%
02/09/24 Free

Chief Executive Officer

3,600,000 1.0027%
02/09/24 Exercice

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-1.10%+15.20%-39.50% 446M
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.43%-1.89%+24.04%+77.64% 59.26B
+1.39%-0.32%+4.61%+34.93% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.48%-0.87%+49.06%+134.71% 39.29B
Weighted average by Cap. +0.01%-0.32%+57.94%+145.52%

Financials

2026 *2027 *
Net sales 2.75M 3.63M 3.23M 3.02M 5.18M 350M 5.25M 36.51M 14.13M 178M 13.64M 13.34M 572M 8.1M 10.7M 9.5M 8.89M 15.25M 1.03B 15.46M 108M 41.63M 525M 40.18M 39.31M 1.69B
Net income -28.92M -38.2M -33.93M -31.73M -54.44M -3.68B -55.19M -384M -149M -1.87B -143M -140M -6.02B -23.64M -31.23M -27.74M -25.94M -44.5M -3.01B -45.11M -314M -121M -1.53B -117M -115M -4.92B
Net Debt -2.43M -3.21M -2.85M -2.66M -4.57M -309M -4.63M -32.21M -12.47M -157M -12.04M -11.77M -505M 16.14M 21.33M 18.94M 17.72M 30.39M 2.05B 30.81M 214M 82.96M 1.05B 80.08M 78.34M 3.36B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
29/09/26 GBX 72.00 -0.69% 614,155
28/09/26 GBX 72.50 -0.41% 532,003
25/09/26 GBX 72.80 -1.62% 1,880,265
24/09/26 GBX 74.00 -1.33% 358,934
23/09/26 GBX 75.00 -.--% 748,154
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7200GBP
Average target price
0.9425GBP
Spread / Average Target
+30.90%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock